CNTB - long - catalyst playConnect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2820 USD
−15.63 M USD
26.03 M USD
About Connect Biopharma Holdings Limited
Sector
Industry
CEO
Barry D. Quart
Website
Headquarters
San Diego
Founded
2015
FIGI
BBG00ZGYNJ49
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.
A Stock on the Brink of Breakthrough?Introduction:
In the ever-evolving landscape of biopharmaceuticals, Connect Biopharma Holdings Limited (NASDAQ: CNTB) emerges as a beacon of potential, navigating through the complexities of drug development with promising advancements and strategic maneuvers. This analysis dives into the core of C
CNTB to Climb to $2Looking at the micro data, we have an uptrend where we're following along the rising bottom.
Looking a bit further out, we can see we're in a bullish wedge.
General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price
CNTB Poised to RocketBetween the multiple products moving from Phase 2 to 3 and looking to hit market soon, and the impending bull market, this BioTech Startup is poised to at least double by the beginning of February. There is going to be a lot more upside to CNTB in the coming year, and I believe we could see so much
Long term holding, hedge fund manipulation detectedIt is part of the sell-out part from the RA Capital group. Derek DiRocco from RA Capital Group stepped down from the Board and in that part, this led to the SEC filing showing RA just sold 1 million shares (label in red circle). The RA capital group still has a lot left to sell but it seems they are
Potential break through $3 scenario for CNTBAfter the good news this morning, the CNTB just got a big dip from one of the whales with weak resistance buyback force resulting in a sum of 3mil shares exchanged between buy and sale leading to a current ~$1.4. However, I noticed a similar pattern around October time where a bullish push for $1.2
New long hold for good startup Biopharma companyWithout looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may si
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.